PACB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Given the user's long-term investment strategy and beginner level, PACB is not a strong buy at the moment. Despite some positive developments like revenue growth and a promising partnership, the significant insider selling, declining net income, and lack of strong trading signals suggest holding off for now.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 57.939, and moving averages are converging, suggesting indecision. Key support is at 1.539, with resistance at 1.914.
PacBio's partnership with DNAstack to create a global platform for HiFi whole genome sequencing data could enhance its reputation and foster growth in the rare disease research market. Revenue increased by 13.82% YoY in Q4 2025.
Pre-market price is down -2.25%, reflecting negative sentiment.
In Q4 2025, revenue grew by 13.82% YoY to $44.645 million, and gross margin improved to 35.26%, up 154.77% YoY. However, net income plummeted by -1802.70% YoY to -$40.371 million, and EPS dropped by -1400.00% YoY to -0.13.
Barclays raised the price target from $1.50 to $2 and maintained an Equal Weight rating. The analyst sees potential for outperformance in the tools group by 2026 but does not indicate strong near-term upside for PACB.
